CSTL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Castle Biosciences Inc (CSTL) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock has positive momentum, strong analyst support, and promising growth potential despite short-term financial challenges.
The stock's MACD is below 0, showing a bearish trend, but it is negatively contracting, which may indicate a potential reversal. RSI is neutral at 51.543, and moving averages are converging, suggesting no strong directional trend. The price is trading near a resistance level (R1: 33.759), with potential upside to R2: 35.326.
Strong Q4 2025 revenue of $87 million and full-year revenue of $344.2 million, with a 37% increase in test report volume.
Positive initial orders for AdvanceAD-Tx test from dermatological accounts.
Management projects 2026 revenue between $340M-$350M, reflecting confidence in future growth.
Analysts have raised price targets multiple times, with the latest targets ranging from $47 to $50, and maintain Buy/Overweight ratings.
Net income dropped significantly in Q4 2025 (-180.17% YoY), and EPS fell to -0.26 (-183.87% YoY).
The MACD indicator remains bearish, and the stock is near resistance, which could limit short-term upside.
No significant hedge fund or insider trading activity to indicate strong institutional confidence.
In Q4 2025, revenue increased slightly by 0.81% YoY to $87.01M, but net income dropped significantly to -$7.69M (-180.17% YoY). EPS also declined to -0.26 (-183.87% YoY). However, gross margin improved slightly to 76.33%. The company has consistently surpassed revenue estimates, indicating operational strength.
Analysts are highly optimistic about CSTL, with multiple firms raising price targets recently. KeyBanc raised the target to $50, Guggenheim to $47, and Canaccord to $50, all maintaining Buy or Overweight ratings. Analysts highlight the company's strong risk-reward profile and growth potential in the diagnostics sector.
